Dr. David Porter, one of the lead authors of the study and director of cell therapy and transplantation at Penn Medicine. "Think of it like the cancer cell has a piece of Velcro on it and the T cell can’t stick to it.
What we’re essentially doing is taking out the patient’s T cells and genetically modifying those to put that other piece of Velcro on the T cell so now, when it recognizes the cancer cell, they can stick together and now that T cell, that immune cell can stick to it and actually kill it," Porter told FOX TV Stations.
Researchers observed just two patients for this study for 10 years and both patients have had no signs of cancer since the start of their treatment in 2010.
After just 30 days following the CAR-T cell therapy, both patients were in remission, according to Porter. FILE - A lab technician works on a research process to find new CAR-T cells and RNA in a laboratory.